FDA cleared Dovato (ViiV Healthcare), the first 2-drug regimen to treat HIV-1 in adults with no antiretroviral treatment history.
Formulary Watch
Latest News
All News
Advertisement
FDA fast-tracks biosimiliar insulin products to elevate competition.
FDA approved 2 new multiple sclerosis drugs. Here's what you should know about them.
Postpartum drug is a game changer, but can women afford it?
Several companies are recalling products due to contamination from substances such as carcinogens and glass-here’s what you should know.
Nasal spray offers promise for treatment-resistant depression, but proceed with caution.
How FDA Chief Gottlieb’s resignation could impact the pharma industry.
Advertisement
The recalls of a widely used hypertension blood drug due to carcinogenic impurities are expanding.
FDA is warning about an increased risk of death and blood clots in the lungs in patients with rheumatoid arthritis taking a specific dosage of this drug.
Many patients who were prescribed fentanyl should not have received the drug, a new study said.
FDA is requiring the addition of a Black Box Warning to a gout drug that has an increased risk of death.
FDA approved first interoperable insulin pump, as well as the only FDA-approved drug for patients with a neglected tropical disease.
In his recent State of the Union address, President Trump promised to continue lowering drug prices and fund research for HIV/AIDS and childhood cancer. Here are the ways experts say he will implement those pledges.
FDA warns companies illegally selling drugs and dietary supplements claiming to cure Alzheimer’s and other conditions.
FDA approved the first generic of a popular inhaler to treat asthma and chronic obstructive pulmonary disease
CVS Health adds new migraine drugs to its list of covered drugs, but excludes one rival treatment.
FDA approves cabozantinib to treat patients with hepatocellular carcinoma, a community in need of new therapeutic options.
A new report details the financial strain rising drug prices are having on patients and hospitals alike.
FDA cleared the first generic tablet version of a top-selling epilepsy drug.
New legislation designed to curb drug costs comes on the heels of many pharma makers raising prices this year as well as payers saying they expect higher drug acquisition costs.
FDA approved a record number of novel treatments in 2018.
Soon after FDA warned the manufacturer involved in a massive nationwide recall of valsartan- and losartan-containing drugs, the recall is expanding. Find out why.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
What IRA drug prices will mean for PBMs, health plans and patients
2
Looking ahead: What the MHE 2025 State of the Industry survey tells us about 2026
3
Biosimilar competition could surpass IRA-negotiated savings by year three
4
The trend toward post-infusion outpatient care of patients treated with CAR-T | ASH 2025
5
